Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis

<span style="color:rgb( 34 , 34 , 34 )">Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these sid...

ver descrição completa

Detalhes bibliográficos
Autores: Mohammadi-Meyabadi, Roya, Mallandrich Miret, Mireia, Beirampour, Negar, Garrós, Núria, Espinoza Tituana, Lupe Carolina, Sosa Díaz, Lilian Elisa, Suñer Carbó, J. (Joaquim), Rodríguez Lagunas, María José, Garduño Ramírez, María Luisa del Carmen, Calpena Campmany, Ana Cristina
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2024
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/217865
Acesso em linha:https://hdl.handle.net/2445/217865
Access Level:Acceso aberto
Palavra-chave:Psoriasi
Malalties de la pell
Lípids
Psoriasis
Skin diseases
Lipids
id ES_652e2bb2a652dac683288d3eda499fa2
oai_identifier_str oai:recercat.cat:2445/217865
network_acronym_str ES
network_name_str España
repository_id_str
spelling Lipid-Based Formulation of Baricitinib for the Topical Treatment of PsoriasisMohammadi-Meyabadi, RoyaMallandrich Miret, MireiaBeirampour, NegarGarrós, NúriaEspinoza Tituana, Lupe CarolinaSosa Díaz, Lilian ElisaSuñer Carbó, J. (Joaquim)Rodríguez Lagunas, María JoséGarduño Ramírez, María Luisa del CarmenCalpena Campmany, Ana CristinaPsoriasiMalalties de la pellLípidsPsoriasisSkin diseasesLipids<span style="color:rgb( 34 , 34 , 34 )">Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. Objectives: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. Methods: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice. Results: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity. Conclusions: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration.</span>MDPI2025202520242025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1 p.application/pdfhttps://hdl.handle.net/2445/217865Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3390/pharmaceutics16101287Pharmaceutics, 2024, vol. 16, num.10https://doi.org/10.3390/pharmaceutics16101287cc-by (c) Roya Mohammadi-Meyabadi et al., 2024http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2178652026-05-29T05:05:01Z
dc.title.none.fl_str_mv Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
title Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
spellingShingle Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
Mohammadi-Meyabadi, Roya
Psoriasi
Malalties de la pell
Lípids
Psoriasis
Skin diseases
Lipids
title_short Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
title_full Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
title_fullStr Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
title_full_unstemmed Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
title_sort Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis
dc.creator.none.fl_str_mv Mohammadi-Meyabadi, Roya
Mallandrich Miret, Mireia
Beirampour, Negar
Garrós, Núria
Espinoza Tituana, Lupe Carolina
Sosa Díaz, Lilian Elisa
Suñer Carbó, J. (Joaquim)
Rodríguez Lagunas, María José
Garduño Ramírez, María Luisa del Carmen
Calpena Campmany, Ana Cristina
author Mohammadi-Meyabadi, Roya
author_facet Mohammadi-Meyabadi, Roya
Mallandrich Miret, Mireia
Beirampour, Negar
Garrós, Núria
Espinoza Tituana, Lupe Carolina
Sosa Díaz, Lilian Elisa
Suñer Carbó, J. (Joaquim)
Rodríguez Lagunas, María José
Garduño Ramírez, María Luisa del Carmen
Calpena Campmany, Ana Cristina
author_role author
author2 Mallandrich Miret, Mireia
Beirampour, Negar
Garrós, Núria
Espinoza Tituana, Lupe Carolina
Sosa Díaz, Lilian Elisa
Suñer Carbó, J. (Joaquim)
Rodríguez Lagunas, María José
Garduño Ramírez, María Luisa del Carmen
Calpena Campmany, Ana Cristina
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Psoriasi
Malalties de la pell
Lípids
Psoriasis
Skin diseases
Lipids
topic Psoriasi
Malalties de la pell
Lípids
Psoriasis
Skin diseases
Lipids
description <span style="color:rgb( 34 , 34 , 34 )">Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. Objectives: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. Methods: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice. Results: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity. Conclusions: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration.</span>
publishDate 2024
dc.date.none.fl_str_mv 2024
2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/217865
url https://hdl.handle.net/2445/217865
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics16101287
Pharmaceutics, 2024, vol. 16, num.10
https://doi.org/10.3390/pharmaceutics16101287
dc.rights.none.fl_str_mv cc-by (c) Roya Mohammadi-Meyabadi et al., 2024
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Roya Mohammadi-Meyabadi et al., 2024
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1 p.
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409723222065152
score 15,812429

Registros relacionados